Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, randomized, multisite, placebo-controlled trial comparing the safety and efficacy of TQ versus placebo in patients hospitalized for babesiosis with low risk for relapsing disease who will also be administered a standard-of-care antimicrobial regimen (A/A) that is recommended in the 2020 IDSA guideline on the diagnosis and management of babesiosis.